Unethical Ass Clowns


























I'm not quite sure why this publication is a big deal. PTI already has medicare approval in the primary/recurrent ovarian cancer subgroup. Why do you need further research in the area where you already have medicare approval and gynonc usage? Whoever already uses ChemoFx is going to keep doing it, and whoever doesn't believe in it probably isn't going to change their mind based on this publication. As someone mentioned above, sure, it's prospective, but the gold standard in clinical research is prospective AND (most importantly) INTERVENTIONAL.

Still, best of luck to everyone at PTI. A lot of good, caring people at that company.